OncoFusion Therapeutics Inc. discovers and develops personalized therapeutics for patients with genetically defined cancers. It focuses on bromodomain inhibitors, ERG inhibitors, EZH-2-EED inhibitors, and MMSET/NSD 2 inhibitors. The company was founded in 2012 and is based in Ann Arbor, Michigan.